What will be the impact of ZYN on cigarette sales by end of 2025?
Significant reduction • 25%
Moderate reduction • 25%
No change • 25%
Increase • 25%
Sales data of cigarettes from industry reports
FDA Authorizes First Nicotine Pouch, ZYN, to Help Adult Smokers Quit
Jan 16, 2025, 07:45 PM
The U.S. Food and Drug Administration (FDA) has authorized the marketing of 20 ZYN nicotine pouch products following an extensive scientific review, marking the first time the agency has approved such products. The authorization comes with stringent marketing restrictions to prevent youth use, and the FDA will closely monitor compliance. The products, which include 10 flavors like coffee, mint, and menthol, are intended for adults aged 21 and older. The FDA's decision is based on evidence showing that ZYN poses a lower risk of cancer and other serious health conditions compared to cigarettes and most smokeless tobacco products. Philip Morris International's ZYN is aimed at helping adult smokers cut back or quit cigarettes, with the FDA noting that a substantial portion of adult smokers have completely switched to these nicotine pouches. However, the FDA clarifies that these products are not considered safe.
View original story
3rd • 25%
1st • 25%
2nd • 25%
Not in top 3 • 25%
6 mg • 25%
3 mg • 25%
Other strengths (if introduced) • 25%
Equal sales • 25%
6 mg • 25%
3 mg • 25%
Other strengths • 25%
Both equally popular • 25%
Other • 25%
ZYN • 25%
Nicotine patches • 25%
Nicotine gum • 25%